Skip to main content

Paolini John F.'s Form 4 filing

Kiniksa Pharmaceuticals International, plc (KNSA) · filed Sep 4, 2024

Accession no.
0001415889-24-022856
Filed
Sep 4, 2024
Trade date
Sep 1-3, 2024
Filing delay
3 days
Rule 10b5-1 plan
Checked

This filing lists 8 non-derivative transactions and 7 derivative transactions. Open-market sales total $1.58M. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Paolini John F.CIK 0001741533Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 1, 2024Class A Ordinary ShareMOption exerciseAcquired+4,121–F1–53,142Direct
Sep 1, 2024Class A Ordinary ShareFTax withholdingDisposed−1,994$26.74−$53,319.5651,148Direct
Sep 2, 2024Class A Ordinary ShareMOption exerciseAcquired+1,725–F1–52,873Direct
Sep 2, 2024Class A Ordinary ShareFTax withholdingDisposed−835$26.74−$22,327.952,038Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseAcquired+60,217$1.86+$112,003.62112,255Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseAcquired+475$3.80+$1,805112,730Direct
Sep 3, 2024Class A Ordinary ShareSSaleDisposed−59,214$26.09F3−$1,544,893.2653,516Direct
Sep 3, 2024Class A Ordinary ShareSSaleDisposed−1,478$27.13F4−$40,098.1452,038Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 1, 2024Class A Ordinary ShareAGrant or awardAcquired+7,000$0.00$07,000Direct
Sep 1, 2024Class A Ordinary ShareAGrant or awardAcquired+36,350$0.00$036,350Direct
Sep 1, 2024Class A Ordinary ShareMOption exerciseDisposed−2,497$0.00$04,995Direct
Sep 1, 2024Class A Ordinary ShareMOption exerciseDisposed−1,624$0.00$04,872Direct
Sep 2, 2024Class A Ordinary ShareMOption exerciseDisposed−1,725$0.00$01,725Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseDisposed−60,217$0.00$00Direct
Sep 3, 2024Class A Ordinary ShareMOption exerciseDisposed−475$0.00$044,549Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Referenced by the price of 2 transactions in Table I.

F3

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $25.88 to $26.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $26.995 to $27.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)